Eugit Therapeutics
ActiveEnabling Tissue Targeting of Therapies
This company has previously operated under “EUGIT Tx”, “EUGIT Therapeutics”, “Eugit”, “Eugit Therapeutics Inc”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Founders · 1
Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.
Related startups
Cell-specific genetic medicines
Our drugs engage the immune system to fight tumors
